Update: Updating estimates on H116, FX moves
We are updating our forecasts for UDG on the back of solid H116 results, the completion of the sale of the drug distribution business and recent pronounced currency moves. While providing a sufficient cash cushion in the current volatile market conditions, the divestment will allow increased flexibility for the company to deliver on its already successful track record of acquisitions. We raise our DCF valuation from £5.21 to £6.45/share.UDG Healthcare is a provider of services to the healthcare industry. Co.'s operations are divided into the following operating segments: Ashfield Commercial & Medical Services, which is engaged in providing sales and marketing services (CSO), healthcare communications, event management, and medical affairs and regulatory services to healthcare companies; Sharp Packaging Services, which is engaged in providing outsourced commercial and clinical trial packaging services to healthcare companies; and Supply Chain Services, which combines all of Co.'s healthcare logistics based companies. Co. operates in Republic of Ireland, the U.K., North America and Continental Europe.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.